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Our objectives were to investigate the possible role of VEGFA in bovine placenta steroid synthesis and to
determine whether cloned derived placental cells present similar responses as non-cloned ones.
Placental cells from cloned (term) and non-cloned (days 90, 150, 210 and term) pregnancies were iso-
lated and treated with VEGFA (50 ng/ml) for 24, 48 or 96 h. Progesterone (P4) and estrone sulfate (E1S)
were assessed by RIA, while aromatase P450-positive cells were quantiﬁed using the point counting test.
The percentages of steroidogenic and non-steroidogenic populations were determined by ﬂow cytom-
etry. VEGFA augmented or decreased P4 and E1S concentrations as well as aromatase P450-positive cell
density, depending on gestational age and time in culture. The percentage of steroidogenic cells was
lower than that of non-steroidogenic ones for each culture time (P < 0.05). VEGFA treatment did not
change the proportion of steroidogenic and non-steroidogenic cells. Placental cells derived from cloned
pregnancies presented higher concentrations of E1S and P4 than the non-cloned group. However, aro-
matase P450-positive cells were similar between groups (P > 0.05). VEGFA treatment altered P4 and E1S
levels in placental cells depending on type of gestation. These results suggest that VEGFA acts locally in
the bovine placenta to modulate steroidogenesis during gestation, but in a different pattern between
cloned and non-cloned derived placental cells at term. Therefore, this factor can be considered an
important regulator of placental development and function.
 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The classic functions of vascular endothelial growth factor A
(VEGFA) are the regulation of cell growth and differentiation and
the control of angiogenesis and neovascularization in organs and
tissues. However, accumulating evidence suggests that this growth
factor may be involved not only in the control of vascular processes
but also in several other developmental and differentiated func-
tions of distinct cell types [1e3]. These ﬁndings have led us to
propose that, in addition to its role in angiogenesis [4], VEGFA may
also have an important role in modulating the functional activity of
bovine placenta, such as steroid hormone production.
Nuclear transfer and related embryo technologies appear to
disturb the normal ontogenic changes in endocrine systems,
modifying fetal endocrine proﬁles [5]. In fact, a previous study: þ55 11 3091 7805.
evier OA license.reported an altered expression of VEGF system in somatic cell
nuclear transfer (SCNT)-derived bovine placentomes at term,which
most likely contribute to the altered placental phenotypes
commonly found in these animals [6]. Based on these ﬁndings, we
hypothesized that SCNT-derived placental cells respond to VEGFA
stimuli differently from control placental cells regarding steroid
production.
Thus, the aim of the present study was to evaluate the inﬂuence
of VEGFA on bovine placenta progesterone (P4) and estrone sulfate
(E1S) synthesis as well as aromatase P450 expression to investigate
if this growth factor induces different steroidogenesis responses in
control and SCNT-derived bovine placental cells.
2. Materials and methods
2.1. Animals and sample collection
Bos indicus multiparous cows had their uteri collected from a nearby abattoir.
The fetal age was estimated by crown-rump length (day 90: 15.6  1 cm; day 150:
38.9  2 cm; day 210: 68.1  2 cm) as described by Sloss and Dufty [7]. Uteri from
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270e274; n ¼ 6) were collected following elective caesarean sections. Cloned
embryos were produced by SCNT [8], whereas non-cloned animals were conceived
by artiﬁcial insemination (AI). Placental anatomical and histological features were
previously described [2,9]. Placentomes were collected (n ¼ 3e4/placenta [10]),
washed several times with fresh saline and transported in sterile phosphate buffer
solution (PBS) pH 7.2e7.4 (0.8 mMNa2HPO4,1.47mMKH2PO4, 2.68 mMKCl,137mM
NaCl) on ice to the laboratory for cell culture. This study was approved by the
Committee in Ethics for the Use of Animals of the Faculty of VeterinaryMedicine and
Animal Sciences, as well as the Faculty of Animal Sciences and Food Engineering of
the University of Sao Paulo (protocol nos. 164/2002 and 858/2006).
2.2. Placental cell culture
Placentomes (fetal and maternal compartments) were diced into 5mm sections,
mechanically dispersed through a 150 mm mesh and incubated in Dulbelcco’s
modiﬁed eagle medium (DMEM) pH 7.2e7.4 (D5523; SigmaeAldrich CO, USA)
containing 280 mM HEPES (391340; Merck KGaA, Darmstadt, Germany), 0.3% L-
glutamine, 7.5% NaHCO3, 1% penicillin-streptomycin-amphotericin B solution
(A5955; SigmaeAldrich), and 5 or 10% fetal bovine serum; (F6178; SigmaeAldrich)
for P4 or E1S analysis, respectively. Homogenates were centrifuged three times
(300  g; 10 min) and re-suspended in DMEM. Viability and cell density were
determined by the trypan blue exclusion method [11]. Subsequently, the cells were
seeded in 96-well culture plates at a density of 5  106 viable cells/0.3 ml and in 24
well plates on collagen-coated glass coverslips for immunocytochemistry. The cells
were incubated at 37 C in a humidiﬁed atmosphere with 5% CO2. After 24 h,
placental cells were divided into two groups: Control and VEGF. For E1S analysis,
cells were treated with 107 M pregnenolone (control group; 20 ng/ml;
SigmaeAldrich) or with pregnenolone plus VEGFA (50 ng/ml; VEGF165, GF025,
Chemicon International Inc., MA, USA). For P4 analysis, culture medium did not
receive pregnenolone [12]. After 24, 48 or 96 h of VEGF addition, culture medium
and cells from each group were collected. For P4 and E1S RIA, medium samples were
immediately frozen at 20 C, while the cells were used for total protein determi-
nations. For aromatase P450 immunocytochemistry, cells were ﬁxed with 95%
methanol for 20 min, washed with PBS and stored at 4 C. Isolated placental cells
from clones C1, C2 and C5 [5] were used for P4 analysis, while clones C3 (male, 53 kg,
287 days of pregnancy, survived), C4 (male, 37 kg, 290 days of pregnancy, survived)
and C6 (male, 63 kg, 290 days of pregnancy, stillborn) were used for E1S
experiments.
2.3. Flow cytometry
Flowcytometrywas used to determine the percentage of steroidogenic and non-
steroidogenic placental cells [13]. Isolated placental cells were prepared for a single-
cell suspension (1 million cells/ml), washed with PBS (2  5 min) and incubated for
30 min on ice with the primary antibody (anti-3bHSD; sc-100466; Santa Cruz
Biotechnology, CA, USA). Afterwards, cell suspensions were centrifuged at 200  g
(2  5 min). The supernatant was discarded and the cells were re-suspended inFig. 1. Estimated aromatase P450-positive bovine placental cell density. An unbiased
counting frame (UCF) is randomly superimposed onto each sampled ﬁeld of view. Each
labeled placental cell (brown chromagen) that came into sharp focus and did not
intercept the full forbidden line of the UFC was counted as a new event. The sum of the
counts (per placenta) was then divided by the total counted area, generating
a numerical density. Bar ¼ 20 mm.100 ml PBS. The secondary antibody (FITC; F0479; Dako, Ca, USA) was added, and the
suspensions were incubated for 30 min in the dark and room temperature, followed
by centrifugation at 200  g (2  5 min). Ten thousand events were analyzed in
a FACSCalibur Flow Cytometer using CellQuestPro software (both Becton Dickinson
Labware, Germany). Controls contained either only buffer or buffer with only
secondary antibody.
2.4. Hormone assay
P4 and E1S concentrations were measured by RIA using commercial solid-phase
kits (DSL 3400 for P4 and DSL 5400 for E1S, Diagnostic Systems Laboratories Inc.,
USA), which produce reliable results for bovine blood plasma [14]. Standard curves
were set up from 0.019 to 5 ng/ml for E1S and 0.03e10 ng/ml for P4. The accuracy of
the antibodies for culturemediumwas checked, demonstrating parallelism between
the dilutions of culture medium and the standard curve. The correlation coefﬁcient
was 0.994 (r2 ¼ 0.988; P < 0.001), and the lowest detectable values (mean sensi-
tivity) of the assays for E1S and P4 were 19 pg/0.1 ml and 0.414 ng/0.1 ml, respec-
tively. The average intra- and inter-assay coefﬁcients of variation were 15.22% andFig. 2. Effect of gestational age (days 90, 150 or 210 or term) on progesterone (ng/mg;
A) and estrone sulfate production (pg/mg; B) and aromatase P450-positive cell density
(C) in bovine placental cells. Progesterone production increased on day 210 and
decreased at term. Estrone sulfate remained constant from day 90e210 and increased
at term. Aromatase P450 remained unchanged at all studied gestational ages.
L.M.M.C. Sousa et al. / Placenta 33 (2012) 788e7947907.41% for E1S and 9.21% and 3.32% for P4, respectively. Concentrations of P4 and E1S in
culture medium at different time points were normalized to the corresponding total
protein content in the respective wells.
2.5. Determination of protein concentration
The total protein concentration of cultured placental cells was determined at
670 nm using bovine serum albumin (BSA) as a standard (from 1 to 0.05 mg/ml), in
triplicate, as previously described [15].
2.6. Immunocytochemistry for aromatase P450
Immunocytochemistry (IHC) was carried out as previously described [16], with
several modiﬁcations. Placental cells were washed with PBS, and endogenous
peroxidase was quenched by incubating the cells in 1% hydrogen peroxide in
methanol for 30 min. They were then rinsed in IHC buffer (PBS plus 0.3% Triton X pH
7.2e7.4 for 3  5 min) and incubated with casein (Protein block Serum-Free, X0909,
Dako) for 20 min at room temperature to block unspeciﬁc binding sites. After
draining of the protein block, cells were overlaid with a polyclonal rabbit anti-
human aromatase P450 primary antibody (1:100; C9095-14A; US Biological, MA,
USA) and incubated overnight at 4 C. After rinsing in IHC buffer for 3  5 min, the
secondary biotinylated antibody (Biotinylated Link; kit Dako LSAB þ System-HRP,
K0679, Dako) was added and incubated for 15 min at room temperature. Cells were
washed in IHC for 3  5 min and incubated with the streptavidineperoxidase
complex (Streptavidin-HRP; kit Dako LSAB þ System-HRP, K0679, Dako) for
15 min at room temperature. After washing in IHC buffer for 3  5 min, the color
reaction was initiated with the substrate (DAB þ Substrate buffer; kit DakoFig. 3. Effects of time in culture (24, 48 or 96 h) and in vitro treatment (0 or 50 ng/ml VEGFA
aromatase P450-positive cell density (G, H, I) at days 90 (ﬁrst line), 150 (second line) and 21
animals per group. Asterisks denote statistically signiﬁcant differences between control an
P < 0.05 for different times in culture within the same gestational age.LSAB þ System-HRP, K0679, Dako), according to the manufacturer’s instructions.
Finally, the slides were washed with tap water twice for 5 min, slightly counter-
stained with hematoxylin and washed under running tap water for 10 min. Bovine
placenta was used as positive control. Negative controls were set up by substituting
the primary antibody with IgG isotype control (Normal rabbit IgG, sc-2027, Santa
Cruz Biotechnology).2.7. Estimating the numerical density of aromatase P450-positive cells
Immunocytochemical glass coverslips were used to obtain the numerical
density of aromatase P450-positive placental cells. Their numerical density was
estimated by the point counting method [17] with the aid of a BX60 Olympus light
microscope (magniﬁcation 100 NA 1.30). An unbiased counting frame was
superimposed onto each selected image (ﬁeld of view), and cells positive for aro-
matase P450 were counted, provided they obeyed the inclusion and exclusion lines
of the frame and were under the maximum focus (Fig. 1). Approximately 5 ﬁelds of
view per glass coverslip were sampled, resulting in an average of 15 ﬁelds of view
per group. Numerical density estimates were calculated using the following
formulas (equations (1) and (2)):




where (AT) is the total area; AFRA is the area of the unbiased counting frame multi-
plied by the total number of frames NFRA divided by the ﬁnal magniﬁcation squared) on progesterone (ng/mg; A, B, C) and estrone sulfate production (pg/mg; D, E, F) and
0 of gestation (third line). Data are presented as the mean  1.96 standard error of six
d treated VEGF cells within the same time in culture (P < 0.05). Where letters differ,
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P
Q is the total number of cells counted
divided by the total area AT.
The total number of cells NTOT was estimated by multiplying the numerical
density with the area of the well plate AREF (equation (3)):
NTOT ¼ NA*AREF (3)
2.8. Statistical analysis
All data are presented as the mean  1.96 standard error. Squared-root
transformation was applied to normalize distributions. Dependent variables were
the in vitro production of progesterone and estrone sulfate and the aromatase
P450-positive cell density. The effects of day of pregnancy (90, 150, 210 or term),
in vitro treatment (0 or 50 ng/ml VEGF), time in culture (0, 24, 48 or 96 h) and
double and triple interactions were tested by ANOVA in a 3  2  4 factorial
arrangement followed by Tukey’s test, or they were tested by Student’s t-test when
pertinent. The effects of type of pregnancy (non-cloned vs. cloned), in vitro treat-
ment (0 or 50 ng/ml VEGF), time in culture (24, 48 or 96 h) and double and triple
interactions were tested in a 2  2  3 factorial arrangement as described above.
Probability values <0.05 were considered statistically signiﬁcant. All calculations
and analyses were performed using GraphPad Prism v.4.0 (GraphPad Software, San
Diego, CA, USA).
3. Results
3.1. Progesterone and estrone sulfate production and aromatase
P450-positive placental cell density
Gestational age had an effect on the in vitro hormone production
(P < 0.0001; Fig. 2). P4 increased at day 210 and decreased at term
(Fig. 2A). In contrast, E1S remained constant through day 210 and
increased at term (Fig. 2B). Time in culture had an effect on E1S
concentration and on aromatase P450-positive cell density
(P < 0.01; Fig. 3). The interaction between time in culture and
gestational age was signiﬁcant for aromatase at all pregnancy ages
and for E1S at 90 and 150 days of gestation (Figs. 3 and 4). An
interaction of in vitro treatment, time in culture and gestational ageFig. 4. Effects of time in culture (24, 48 or 96 h) and in vitro treatment (0 or 50 ng/ml VEGFA)
aromatase P450-positive cell density (C and F) in non-cloned (A, B, C) and cloned term deriv
control and treated VEGF cells within the same time in culture (P < 0.05). Where letters dwas detected (P < 0.05). VEGFA supplementation altered hormone
production and aromatase P450-positive cells at speciﬁc time
points. On pregnancy day 210, VEGFA increased P4 concentration at
24 h and reduced it at 48 h (Fig. 3C). E1S productionwas stimulated
by VEGFA only at day 90 after 96 h (P < 0.05; Fig. 3D). In addition,
the number of aromatase P450-positive cells was augmented by
VEGFA at pregnancy day 90 after 24 h (Fig. 3G) and inhibited at day
150 after 48 h (Fig. 3H) in comparison to the respective untreated
control.
3.2. Progesterone and estrone sulfate production in placental cells
from cloned bovine placenta after VEGFA treatment
In placental cells derived from cloned animals, time in culture
had an effect on E1S concentration and on aromatase P450-positive
cell density (P < 0.05; Fig. 4). E1S decreased and aromatase P450-
positive cell density increased as time in culture increased
(Fig. 4E and F). VEGFA addition did not exert any effect on P4
(Fig. 4D). However, E1S decreased at 24 h of treatment compared to
the control (Fig. 4E). There was no effect of cloning on aromatase
P450-positive cell density (P> 0.05; Fig. 5C). However, regardless of
in vitro treatment and time in culture, P4 was 50% higher and
estrone sulfate was twice as high in cloned animals (P < 0.001;
Fig. 5A and B).
3.3. Flow cytometry analysis
Flow cytometry analysis on placenta was available from day 210
of pregnancy. The percentage of steroidogenic cells was lower than
that of non-steroidogenic cells throughout the culture (5.94%  0.5
vs. 8.71%  0.5 at 0 h; 5.19%  0.98 vs. 13.35%  0.98 at 24 h;
5.48%  0.83 vs. 16.01%  0.83 at 48 h; and 1.62%  0.84 vs.
5.58%  0.84 at 96 h; P < 0.05). Decreases in the amounts of bothon progesterone (ng/mg; A and D) and estrone sulfate production (pg/mg; B and E) and
ed placental cells (D, E, F). Asterisks denote statistically signiﬁcant differences between
iffer, P < 0.05 for different times in culture according to the type of pregnancy.
Fig. 5. Effect of type of pregnancy (cloned and non-cloned) on progesterone (ng/mg;
A) and estrone sulfate production (pg/mg; B) and aromatase P450-positive cell density
(C). Values are means  1.96 standard error of 6 animals per group. Asterisks denote
statistically signiﬁcant differences (P < 0.05) between cloned and non-cloned
gestations.
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culture (P < 0.05). Furthermore, VEGFA addition did not change the
proportions of steroidogenic and non-steroidogenic cells.4. Discussion
VEGFA is considered the most important factor promoting
placental angiogenesis and vasculogenesis [18]. In the present
study, however, we demonstrated a new possible extracellular
action of VEGFA in the bovine placenta, i.e., modulating placental
steroidogenesis. The VEGFA gene and VEGF peptides are expressed
in bovine placenta [2,19,20]. Cellular localization in non-endothelial
cells and time-dependent changes in the expression of this growth
factor in the placenta suggest its participation in physiological
functions in addition to its well-known effects on cell proliferation
and angiogenesis.The inﬂuence of growth factors in the modulation of hormone
synthesis in distinct endocrine cell types has been described
[21e24]. However, the mechanisms involved are not completely
elucidated. According to Li and Johnson [25], bFGF inhibits
androstenedione production in chicken granulosa cells via inhibi-
tion of P450c17a expression. In addition, Kobayashi et al. [21]
suggest that, in bovine CL endothelial cells, the production of
angiotensin II and prostaglandin F2a are up-regulated by bFGF and
VEGF and that their interactions ensure progesterone production in
the developing CL. An additional study using bovine CL reported
decreases in plasma P4 and STAR expression after in vivo treatment
using anti-VEGF antibody [26]. In bovine placental cells, we
observed that the concentrations of P4 and E1S changed depending
on the gestational age after VEGFA addition. At day 90, for example,
P4 and E1S increased after treatment. At this stage, at which the
placenta grows rapidly, a peak of VEGFA expression is observed [2].
In parallel, the plasma concentrations of estrogens start to rise
[27e29], supporting caruncular growth and differentiation [30]. In
addition, progesterone levels increase once the maternal caruncle
cells begin to produce substantial quantities of this hormone [31].
At day 210 in this study, the P4 and E1S concentrations were,
respectively, increased and decreased in response to VEGFA addi-
tion. An increase in progesterone synthesis by the bovine placenta
after day 200 of pregnancy is necessary for its maintenance because
the activity of the corpus luteum declines dramatically by mid-
gestation [32]. During this period, the activity of HSD3B increases
([33]), and STAR expression and P4 synthesis increase concurrently
[34e37]. We suggest that VEGFA can act as a local regulator of this
process, most likely by modulating the expression of steroidogenic
enzymes other than aromatase P450. At term, the concentration of
estrone sulfate, which serves as a reservoir for the formation of
more active circulating estrogens [38], decreased, and the number
of aromatase P450-positive cells increased after treatment. These
results suggest an augmentation of estrogen synthesis. The
concentration changes of P4 and E1S caused by VEGFA in the
present study agree with data present by Izhar et al. [31] and Zhang
et al. [39], who concluded that these changes might reﬂect the
placenta’s ability to produce steroid hormones.
The analysis of the cellular capacity to produce steroid
hormones at term indicated that the estrone sulfate concentration
was twice as high and that P4 increased by 50% in cloned placenta
compared with non-cloned placenta. Furthermore, the density of
aromatase P450-positive cells was similar between cloned and
non-cloned placenta. Plasma progesterone concentrations are
similar in cloned and non-cloned pregnancy recipients [24,40].
Although P4 concentration is elevated in SCNT recipients [41,42]
and is correlated with birth weight, as observed in some of SCNT
fetuses of the present study [5], elevated P4 production by cloned
placenta cells may also depend on disrupted control mechanisms
that are observed in vitro but not in vivo [43]. The elevated E1S
observed in our study agrees with the results of Hirayama et al.
[24], who observed that plasma E1S tended to be higher in cows
carrying SCNT-derived fetuses, while estrone (E1) and estradiol-17b
(E2) tended to be lower than those in AI controls during the pre-
parturition period. E1S is an inactive form of estrogen whose
production is catalyzed by estrogen sulfotransferase (EST), the
activity of which is detected mainly in fetal cotyledonary tissue
[44]. Conversely, sulfoconjugated estrogens may also be precursors
of the production of free estrogens, depending on estrogen sulfa-
tase activity (StS) [30,45]. According to Hirayama et al. [24],
placental expression levels of StS and CYP19 do not differ between
SCNT and AI pregnancies, suggesting that StS and CYP19 contribute
to the progression of parturition by desulfation and de novo
synthesis of estrogen, respectively. However, the expression of
sulfotransferase is higher in SCNT placentomes, suggesting that
L.M.M.C. Sousa et al. / Placenta 33 (2012) 788e794 793excessive placental sulfoconjugation might inhibit the pre-partum
rise of active estrogens, causing a poor sign of parturition and
prolonged pregnancy in SCNT pregnancies. Based on the above
ﬁndings, another reason for the higher estrone sulfate observed in
cells derived from cloned placenta might reﬂect the ability of these
cells to hydrolyze estrone sulfate.
In summary, P4 and E1S concentrations as wells as the density of
aromatase P450-positive cells changed after VEGFA treatment
depending on the time in culture and gestational age. Furthermore,
cloned derived placental cells responded differently from non-
cloned derived ones, especially in E1S and P4 production. These
ﬁndings suggest that VEGFA acts locally in the bovine placenta to
modulate steroid hormone synthesis, which indicates that this
factor has an important role as a regulator of placental develop-
ment and function.
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